Kudo, M., Ueshima, K., Chiba, Y., Ogasawara, S., Obi, S., Izumi, N., . . . Arai, Y. (2019). Objective Response by mRECIST Is an Independent Prognostic Factor for Overall Survival in Hepatocellular Carcinoma Treated with Sorafenib in the SILIUS Trial. Liver Cancer.
Citação norma ChicagoKudo, Masatoshi, et al. "Objective Response By MRECIST Is an Independent Prognostic Factor for Overall Survival in Hepatocellular Carcinoma Treated With Sorafenib in the SILIUS Trial." Liver Cancer 2019.
MLA CitationKudo, Masatoshi, et al. "Objective Response By MRECIST Is an Independent Prognostic Factor for Overall Survival in Hepatocellular Carcinoma Treated With Sorafenib in the SILIUS Trial." Liver Cancer 2019.
Advarsel: Disse citationer er muligvist ikke 100% nøjagtige.